Skip to content

Efficacy and safety of Hehuan Anshen Granules for Chronic Insomnia with Daytime Fatigue: A randomized, Double-Blind, Controlled Trial

Efficacy and safety of Hehuan Anshen Granules for Chronic Insomnia with Daytime Fatigue: A randomized, Double-Blind, Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000197
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-05-11
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic insomnia

Interventions

Controlled group:Hehuan Anshen granules with a 10% drug concentration
Experimental group:Hehuan Anshen granules

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 81 Years

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged >= 18 years; 2. Clear consciousness normal hearing and visual abilities are maintained and have the ability to participate in the neuropsychological activity test; 3. Participants meet diagnostic criteria for Chronic insomnia in ICSD-3 and with daytime fatigue at the same time. 4. According to the "internal medicine of traditional Chinese medicine" it meets the diagnostic criteria of "insomnia disease" and conforms to the syndrome types of liver fire disturbing the heart phlegm heat disturbing the heart deficiency of both heart and spleen heart kidney disharmony deficiency of heart and gallbladder Qi etc. 5.The total score of PSQI is above 8; 6. The total score of FFS is above 14; 7. Participants agree to sign the informed consent form and volunteer for this study

Exclusion criteria

Exclusion criteria: (1) Participants with other sleep disorders such as narcolepsy sleep apnea syndrome or sleep related motor disorders; (2) Participants with Any history of severe mental illness; (3) Participants with obvious depressive symptoms with a score of>29 on the Beck Depression Inventory II (BDI) Depression Scale; (4) Participants with medication alcohol dependence addiction or allergies to the drugs in this study; (5)Participants were taking antipsychotic medication that impact the assessment of efficacy; (6) Any participant on treatment were withdrawn from other clinical drug trials before the first study-drug administration were less than 2 weeks. (7) Participants with serious gastrointestinal diseases (such as indigestion gastrointestinal obstruction gastroduodenal ulceration) and serious secondary diseases that affect drug absorption; (8) Participants comprised hepatic and renal dysfunction severe neurological diseases cardiovascular and cerebrovascular diseases' complication as well as a history of other autoimmune diseases and any other contraindication; (9) Female participants who are pregnant breastfeeding or may not be able to take effective contraceptive measures during research

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Index Scale;

Secondary

MeasureTime frame
Fatigue Severity Scale;Traditional Chinese Medicine Symptom Scale;Flinders Fatigue Scale;Insomnia Severity Scale;

Countries

China

Contacts

Public ContactXu Jian

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of TCM

xujian0296@163.com+86 139 0178 1509

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026